Join BIOCYTOGEN at IMMUNOLOGY (AAI) 2025

Join BIOCYTOGEN at IMMUNOLOGY (AAI) 2025

We’re thrilled to announce that Biocytogen will be showcasing our innovations at IMMUNOLOGY (AAI) 2025! Join us May 4–6 in beautiful Honolulu, Hawaii, for this premier event that gathers industry leaders and trailblazers in biotechnology. With unmatched opportunities for networking, this conference unites scientists, investors, and biopharmaceutical experts to drive collaboration and advance groundbreaking research in immunology and beyond. Let’s connect and shape the future of life sciences together—see you there!

What is IMMUNOLOGY (AAI) 2025?

IMMUNOLOGY (AAI) 2025 hosts the world’s largest annual all-immunology meeting, bringing together scientists from more than 40 countries who are at all career stages— from international leaders to the next generation of scientists. Over 3,500 scientists are expected to attend IMMUNOLOGY 2025 to hear about cutting-edge science and learn of innovations and products that can benefit their research programs. 

Event Overview  

Date: May 3th–7th 

Venue: Hawaii Convention Center, 1801 Kalakaua Ave, Honolulu, HI 96815

Event Schedule

The IMMUNOLOGY (AAI) 2025 in Honolulu, Hawaii will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the IMMUNOLOGY (AAI) 2025.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

We look forward to seeing you at the IMMUNOLOGY (AAI) 2025 in Honolulu, Hawaii!

Share:

Back to top
WordPress Double Opt-in by Forge12